A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

NCT03548467 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumours

Interventions

BIOLOGICAL: VB10.NEO
DRUG: Bempegaldesleukin

Sponsor

Nykode Therapeutics ASA

Collaborators

[object Object]
[object Object]